In this cost-effectiveness analysis, population-wide screening for CKD combined with ACE inhibitors or ARBs along with SGLT2 inhibitors over ages 55 to 75 years was estimated to have large population health benefits, was cost-effective, and narrowed CKD disparities across 4 racial and ethnic groups. Here, SLC5A2 is linked to chronic kidney disease.